Redirecting host preexisting influenza A virus immunity for cancer immunotherapy

Keyphrases

• Cancer Immunotherapy 100%
• Influenza Virus 100%
• Antiviral Immunity 100%
• Influenza A 100%
• Human Epidermal Growth Factor Receptor 2 (HER2) 42%
• Tumor Metastasis 42%
• Puerto Rico 42%
• Targeted Tumor 28%
• Tumor 28%
• MHC Class II 28%
• Tumor Growth 28%
• Syngeneic 28%
• Systemic Delivery 28%
• Inhibit Tumor 28%
• Lipid Nanoparticles 28%
• Mammary Tumor 28%
• Hemagglutinin 28%
• Nucleoprotein 28%
• Clinical Translation 14%
• Overexpressing 14%
• Therapy Approaches 14%
• Ectopic Expression 14%
• Further Development 14%
• Tumor Inhibition 14%
• Antigen Presentation 14%
• Antitumor Activity 14%
• Nave 14%
• Systemic Administration 14%
• Lentiviral Transduction 14%
• Influenza 14%
• Virus Strains 14%
• Repurposing 14%
• Systemic Therapy 14%
• Mammary Tumor Cells 14%
• Strong Inhibition 14%

Medicine and Dentistry

• Cancer Immunotherapy 100%
• Influenza A Virus 100%
• Influenza A 100%
• Virus Immunity 100%
• Tumor 85%
• Tumor Progression 42%
• Metastatic Carcinoma 42%
• Epidermal Growth Factor Receptor 2 42%
• Gamma Urogastrone 42%
• Nanoparticle 28%
• Major Histocompatibility Complex 28%
• Hemagglutinin 28%
• Nucleoprotein 28%
• Systemic Therapy 14%
• Antigen Presentation 14%
• Breast Tumor 14%
• Antineoplastic Activity 14%
• Systemic Administration 14%
• Ectopic Expression 14%
• Virus Strain 14%
• Viral Immunity 14%

Immunology and Microbiology

• Influenzavirus A 100%
• Influenza 100%
• Cancer Immunotherapy 100%
• Virus Immunity 100%
• Peptides 50%
• Gamma Urogastrone 37%
• Major Histocompatibility Complex 25%
• Syngenic 25%
• Hemagglutinin 25%
• Nucleoprotein 25%
• Antigen Presentation 12%
• Ectopic Expression 12%
• Tumor Cell 12%
• Antineoplastic Activity 12%
• Virus Strain 12%
• Viral Immunity 12%